Vemurafenib CAN be Co-Administered with the Following Agents, IF Administered with Caution1,2
- Agents with narrow therapeutic windows that are metabolised by CYP1A2, CYP2D6 and CYP3A4
- The CYP2C9 substrate warfarin
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole)
- Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)
Additional Important Information when Prescribing Vermurafenib1-3
If co-administration of CYP1A2, CYP2D6 and CYP3A4 substrate drugs cannot be avoided, exercise caution and consider a dose reduction of the concomitant CYP1A2 and CYP2D6 substrate drug.
References
- European Medicines Agency. Vemurafenib (ZELBORAF). Summary of Product Characteristics. 2015.
- Food and Drug Administration. Vemurafenib (ZELBORAF) Prescribing information. 2015.
- van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15: e315-326.